Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C11H18N4O3
CAS Number:
Molecular Weight:
254.29
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Product Name
Pimonidazole, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
color
yellow
solubility
DMSO: >20 mg/mL
storage temp.
2-8°C
SMILES string
OC(CN1CCCCC1)Cn2ccnc2[N+]([O-])=O
InChI
1S/C11H18N4O3/c16-10(8-13-5-2-1-3-6-13)9-14-7-4-12-11(14)15(17)18/h4,7,10,16H,1-3,5-6,8-9H2
InChI key
WVWOOAYQYLJEFD-UHFFFAOYSA-N
Biochem/physiol Actions
Pimonidazole is an effective and nontoxic exogenous 2-nitroimidazole hypoxia marker.
Pimonidazole is an effective and nontoxic exogenous 2-nitroimidazole hypoxia marker. Pimonidazole forms adducts with thiol groups in proteins, peptides and amino acids.
Pimonidazole possesses a nitro group at position 2 and an imidazole ring. Pimonidazole undergoes reduction and is activated in hypoxic cells.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Hypoxia Studies with Pimonidazole in vivo
Aguilera KY and Brekken RA
Bio-protocol, 4(19) (2014)
Investigations into Hypoxia and Oxidative Stress at the Optic Nerve Head in a Rat Model of Glaucoma.
Glyn Chidlow et al.
Frontiers in neuroscience, 11, 478-478 (2017-09-09)
The vascular hypothesis of glaucoma proposes that retinal ganglion cell axons traversing the optic nerve head (ONH) undergo oxygen and nutrient insufficiency as a result of compromised local blood flow, ultimately leading to their degeneration. To date, evidence for the
Lena-Christin Conradi et al.
Angiogenesis, 20(4), 599-613 (2017-09-07)
Blockade of the glycolytic activator PFKFB3 in cancer cells (using a maximum tolerable dose of 70 mg/kg of the PFKFB3 blocker 3PO) inhibits tumor growth in preclinical models and is currently being tested as a novel anticancer treatment in phase I
